2020
DOI: 10.1001/jamapsychiatry.2020.0114
|View full text |Cite|
|
Sign up to set email alerts
|

A Framework for Advancing Precision Medicine in Clinical Trials for Mental Disorders

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
24
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5
3
1

Relationship

1
8

Authors

Journals

citations
Cited by 43 publications
(24 citation statements)
references
References 10 publications
0
24
0
Order By: Relevance
“…Similarly, such models may be useful to determine who would benefit from treatments that affect serotonergic tone. Ultimately, by measuring a more specific, biologically based phenotype, there is greatly improved opportunity to improve sensitivity of measurement and specificity of treatment [25].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Similarly, such models may be useful to determine who would benefit from treatments that affect serotonergic tone. Ultimately, by measuring a more specific, biologically based phenotype, there is greatly improved opportunity to improve sensitivity of measurement and specificity of treatment [25].…”
Section: Discussionmentioning
confidence: 99%
“…Such measures should strive to be easy to collect, have increased sensitivity to facilitate frequent and accurate assessment, and should be validated in relationship to narrower biological phenotypes and treatment targets than traditional endpoints offer. This will lead to improved dynamic treatment research and clinical decision making [24] based on modulation of underlying neurobiological deficits [25].…”
Section: Introductionmentioning
confidence: 99%
“…The authors did find that the simulated PTR produced better effects. Lenze et al (2020) address the problems of RCTs from a somewhat different perspective than I have presented here and suggest a potential solution that they call precision clinical trials (PCTs). The authors propose that the problem with most existing RCTs is that they measure only the fixed baseline characteristics that are not usually sensitive to detecting treatment responders.…”
Section: Solutions To the Problem Of The Primacy Of Rctsmentioning
confidence: 98%
“…On the basis of this finding, Everaert and Joormann (2019) provided an example of a testable prediction about which symptoms to target with which strategy based on their network analysis: "If patients display symptoms related to negative expectations about the future (e.g., pessimism, fear of the worst happening), then treatments may adopt a symptom-focused strategy and increase positive reappraisal use (e.g., through cognitive restructuring) to obtain relief in these specific symptoms" (p. 10). As such, data-derived hypotheses generated via network analysis of symptommechanism interactions can function as an intermediate low-burden step that can guide the development of precision clinical trials, which require focalized targets, adaptive approaches, and precise measurement of mechanisms and outcomes (Lenze et al, 2020).…”
Section: Introductionmentioning
confidence: 99%